Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- US Pharm. Market Up 5.1% to US$300 Bil. in 2009: IMS Health
April 26, 2010
- 23% of Pharmacies Aim at Generic Usage Rate of Over 30%
April 26, 2010
- MTPC Ordered to Suspend Business for 25 Days
April 26, 2010
- Taiyo Puts End to “One-Stop Generic Company”Policy
April 26, 2010
- Symyx to Introduce ELE to Japanese Companies
April 26, 2010
- Ethical Drugs Sales Up 2.3% in Jan., Flat in Feb.: Crecon
April 26, 2010
- Effects on MTPC's Business Performance Remain Unpredictable
April 26, 2010
- Osaka Bio Fund Inaugurated
April 26, 2010
- Administrative Sanction on MTPC Too Harsh: Mr Gohara
April 26, 2010
- Korosho Asks 4 Companies to Develop IPV
April 26, 2010
- Toho HD to Merge Asucome in October
April 26, 2010
- Carna Biosciences' R&D Project to Be Funded by NIBIO
April 26, 2010
- Mochida Terminates License Agreement for TRPV1 Antagonists with Wyeth
April 26, 2010
- CMIC Licenses L-FABP Diagnostic Technology to Genzyme
April 26, 2010
- AnGes to Discuss Licensing of ILTS with MEDRx
April 26, 2010
- BI Successfully Completes Tender Offer on SSP
April 26, 2010
- GSK Opens Rare Diseases Medicine Development Center in Japan
April 26, 2010
- Kenko.com Appeals Aiming at Online Sale of Classes 1, 2 OTC Drugs
April 26, 2010
- Shionogi's Demand Rejected in Flomox Patent Litigation
April 26, 2010
- Kenporen Members to Report Record-High Deficit of ¥660 Bil.
April 26, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…